Breaking Finance News

A statement released earlier today by H.C. Wainwright about Mirati Therapeutics (NDAQ:MRTX) bumps the target price to $20.00

Stating a potential upside of 0.42%, H.C. Wainwright upped the price target of Mirati Therapeutics (NDAQ:MRTX) to $20.00

On Tuesday September 19, 2017, Oppenheimer released a statement on Mirati Therapeutics (NDAQ:MRTX) upped the target price from $0.00 to $18.00 that suggested an upside of 0.69%.

Having a price of $14.13, Mirati Therapeutics (NDAQ:MRTX) traded -1.74% lower on the day. With the last close up 164.00% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. Mirati Therapeutics has recorded a 50-day average of $8.95 and a two hundred day average of $5.36. Volume of trade was down over the average, with 681,216 shares of MRTX changing hands under the typical 1,287,920

Performance Chart

Mirati Therapeutics (NDAQ:MRTX)

With a total market value of $0, Mirati Therapeutics has with a one year low of $2.70 and a one year high of $15.50 .

A total of 7 analysts have released a research note on Mirati Therapeutics. Four analysts rating the company a strong buy, two analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $30.43.

More About Mirati Therapeutics (NDAQ:MRTX)

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *